{"id":"insulin-glargine-combined-with-metformin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Hypoglycemia"},{"rate":"2-5","effect":"Weight gain"},{"rate":"10-30","effect":"Gastrointestinal disturbance (metformin component)"},{"rate":"1-5","effect":"Injection site reactions"},{"rate":"<0.1","effect":"Lactic acidosis (rare, metformin-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glargine is a long-acting basal insulin that mimics endogenous insulin secretion to lower blood glucose. Metformin is a biguanide that decreases hepatic gluconeogenesis and enhances peripheral insulin sensitivity. Together, they address both insulin deficiency and insulin resistance in type 2 diabetes management.","oneSentence":"This combination uses insulin glargine to provide basal insulin replacement while metformin reduces hepatic glucose production and improves insulin sensitivity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:14.751Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT06881264","phase":"PHASE3","title":"A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-04-30","conditions":"Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","enrollment":401},{"nctId":"NCT06871761","phase":"PHASE3","title":"A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05-08","conditions":"Adult Patients With Type 2 Diabetes","enrollment":393},{"nctId":"NCT06688123","phase":"PHASE2","title":"Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-01-08","conditions":"Type 2 Diabetes","enrollment":275},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT06007014","phase":"NA","title":"Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2023-10-31","conditions":"Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM Patients, Metformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect, 128 Patients Were Randomly Assigned 1:1","enrollment":128},{"nctId":"NCT01760447","phase":"PHASE3","title":"A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-12-07","conditions":"Type 2 Diabetes Mellitus","enrollment":223},{"nctId":"NCT04893148","phase":"PHASE4","title":"Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2020-05-26","conditions":"Type 2 Diabetes Mellitus, Glucose, High Blood","enrollment":40},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT03798080","phase":"PHASE3","title":"Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-19","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03798054","phase":"PHASE3","title":"Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-02-15","conditions":"Type 2 Diabetes Mellitus","enrollment":878},{"nctId":"NCT03359837","phase":"PHASE4","title":"Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":384},{"nctId":"NCT03529123","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-19","conditions":"Type 2 Diabetes Mellitus","enrollment":247},{"nctId":"NCT02787551","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-06","conditions":"Type 2 Diabetes Mellitus","enrollment":514},{"nctId":"NCT02623998","phase":"PHASE3","title":"Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2016-07-09","conditions":"Type 2 Diabetes Mellitus","enrollment":102},{"nctId":"NCT03922750","phase":"PHASE2","title":"A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-09","conditions":"Diabetes Mellitus, Type 2","enrollment":154},{"nctId":"NCT02250794","phase":"PHASE4","title":"Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2014-10","conditions":"Type 2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT02922179","phase":"","title":"Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics","status":"COMPLETED","sponsor":"Biologics & Biosimilars Collective Intelligence Consortium","startDate":"2011-01-01","conditions":"Diabetes","enrollment":103951},{"nctId":"NCT03951805","phase":"PHASE2","title":"A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-05-09","conditions":"Diabetes Mellitus, Type 2","enrollment":205},{"nctId":"NCT03751657","phase":"PHASE2","title":"A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2018-11-29","conditions":"Diabetes Mellitus, Type 2","enrollment":247},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT03819790","phase":"PHASE4","title":"The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians","status":"COMPLETED","sponsor":"LMC Diabetes & Endocrinology Ltd.","startDate":"2018-10-02","conditions":"Diabetes Mellitus, Type 2","enrollment":119},{"nctId":"NCT02752412","phase":"PHASE3","title":"Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-05-17","conditions":"Type 2 Diabetes Mellitus","enrollment":513},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT01850615","phase":"PHASE3","title":"Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-23","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":323},{"nctId":"NCT02470039","phase":"PHASE2","title":"Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-06-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":50},{"nctId":"NCT02738879","phase":"PHASE3","title":"Randomized Sitagliptin Withdrawal Study (MK-0431-845)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-05-09","conditions":"Type 2 Diabetes Mellitus","enrollment":746},{"nctId":"NCT02453685","phase":"PHASE4","title":"A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":335},{"nctId":"NCT01819129","phase":"PHASE3","title":"Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-09-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":881},{"nctId":"NCT02954692","phase":"PHASE4","title":"A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-30","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT02467920","phase":"PHASE4","title":"Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2015-08","conditions":"Type 2 Diabetes Mellitus","enrollment":349},{"nctId":"NCT01792830","phase":"PHASE3","title":"Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients","status":"COMPLETED","sponsor":"Emory University","startDate":"2012-10","conditions":"Poor Glycemic Control","enrollment":175},{"nctId":"NCT02099110","phase":"PHASE3","title":"Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-04-22","conditions":"Type 2 Diabetes Mellitus","enrollment":1233},{"nctId":"NCT01462266","phase":"PHASE3","title":"Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-01-13","conditions":"Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT02147925","phase":"PHASE4","title":"Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2014-08","conditions":"Non-alcoholic Fatty Liver Disease","enrollment":75},{"nctId":"NCT02420262","phase":"PHASE3","title":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-07-26","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":506},{"nctId":"NCT01845831","phase":"PHASE4","title":"Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2013-08","conditions":"Type 2 Diabetes","enrollment":292},{"nctId":"NCT02058147","phase":"PHASE3","title":"Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-02","conditions":"Type 2 Diabetes","enrollment":1170},{"nctId":"NCT02058160","phase":"PHASE3","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":736},{"nctId":"NCT01849289","phase":"PHASE3","title":"A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2013-06-02","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":833},{"nctId":"NCT00614055","phase":"PHASE2","title":"Comparison of Two NN5401 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":178},{"nctId":"NCT00909480","phase":"PHASE4","title":"Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2009-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":457},{"nctId":"NCT00611884","phase":"PHASE2","title":"Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Metformin in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":245},{"nctId":"NCT00184626","phase":"PHASE4","title":"Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2004-09-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":97},{"nctId":"NCT00402909","phase":"PHASE4","title":"Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-11","conditions":"Type 2 Diabetes","enrollment":28},{"nctId":"NCT01123980","phase":"PHASE4","title":"Comparison of the Blood Sugar Lowering Effect of Biphasic Insulin Aspart 30 and Insulin Glargine Both Combined With Metformin and Glimepiride in Chinese and Japanese Subjects With Type 2 Diabetes New to Insulin Treatment","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":521},{"nctId":"NCT00469092","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":480},{"nctId":"NCT00331851","phase":"PHASE3","title":"Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-05","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":584},{"nctId":"NCT00097877","phase":"PHASE3","title":"Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":293},{"nctId":"NCT00619697","phase":"PHASE4","title":"Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2003-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":260},{"nctId":"NCT01045707","phase":"PHASE3","title":"Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":530},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01051011","phase":"PHASE3","title":"A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Diabetes Mellitus Type 2","enrollment":370},{"nctId":"NCT02887625","phase":"NA","title":"Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM","status":"UNKNOWN","sponsor":"Dr. Muhammad Abdulghani","startDate":"2015-02","conditions":"Type 2 Diabetes","enrollment":410},{"nctId":"NCT00755287","phase":"PHASE3","title":"A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11","conditions":"Diabetes Mellitus Type 2","enrollment":1072},{"nctId":"NCT02026310","phase":"NA","title":"Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment","status":"COMPLETED","sponsor":"Qifu Li","startDate":"2014-01","conditions":"Diabetes Mellitus, Type 2","enrollment":40},{"nctId":"NCT02526810","phase":"PHASE4","title":"Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes","status":"UNKNOWN","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-07","conditions":"Diabetes Mellitus, Type 2","enrollment":70},{"nctId":"NCT00641056","phase":"PHASE3","title":"Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-04","conditions":"Type 2 Diabetes Mellitus","enrollment":467},{"nctId":"NCT00082381","phase":"PHASE3","title":"Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-06","conditions":"Diabetes Mellitus, Type 2","enrollment":551},{"nctId":"NCT01421459","phase":"PHASE3","title":"A Study in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-09","conditions":"Diabetes Mellitus, Type 2","enrollment":759},{"nctId":"NCT01278160","phase":"PHASE4","title":"Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2011-01","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":179},{"nctId":"NCT01011868","phase":"PHASE2","title":"Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":494},{"nctId":"NCT00970528","phase":"PHASE4","title":"Glucose Reduction by Early Acarbose Treatment in Basal Insulin","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":124},{"nctId":"NCT01974544","phase":"NA","title":"Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2013-05","conditions":"Type 2 Diabetes","enrollment":150},{"nctId":"NCT00474838","phase":"PHASE4","title":"Study To Evaluate Beta Cell Function and Glycemic Outcome by Intensive Insulin Therapy","status":"COMPLETED","sponsor":"Kyunghee University Medical Center","startDate":"2007-04","conditions":"Type 2 Diabetes Mellitus, Pancreatic Beta Cell Function, Glucotoxicity","enrollment":112},{"nctId":"NCT00913367","phase":"PHASE4","title":"Efficacy/Safety Study of Amaryl®M 1/500 mg Twice Daily Versus Amaryl® 4 mg Both in Combination With Lantus® in Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2009-05","conditions":"Type 2 Diabetes Mellitus","enrollment":110},{"nctId":"NCT00667732","phase":"PHASE4","title":"How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2007-03","conditions":"Type 2 Diabetes","enrollment":41},{"nctId":"NCT00851903","phase":"PHASE3","title":"Evaluation of Insulin Glargine in Combination With Sitagliptin in Type 2 Diabetes Patients: EASIE Extension Trial","status":"COMPLETED","sponsor":"Sanofi","startDate":"2009-06","conditions":"Diabetes Mellitus, Type 2","enrollment":112},{"nctId":"NCT00708578","phase":"PHASE4","title":"Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-05","conditions":"Type 2 Diabetes Mellitus","enrollment":99},{"nctId":"NCT00046462","phase":"PHASE3","title":"Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-11","conditions":"Diabetes Mellitus","enrollment":240},{"nctId":"NCT01206647","phase":"PHASE4","title":"Investigation of a Switch From Insulin Therapy to a Metformin & Saxagliptin Combination in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"ikfe-CRO GmbH","startDate":"2010-02","conditions":"Diabetes Mellitus, Type 2","enrollment":120},{"nctId":"NCT00770445","phase":"PHASE4","title":"Efficacy of Pioglitazone and Metformin on Cardiovascular Risk in Subjects With Insulin-Treated Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"Takeda","startDate":"2008-05","conditions":"Diabetes Mellitus","enrollment":121},{"nctId":"NCT00783744","phase":"PHASE3","title":"Insulin Glargine Combination Therapies in Type II Diabetics","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-12","conditions":"Diabetes Mellitus, Type 2","enrollment":375},{"nctId":"NCT00347100","phase":"PHASE4","title":"Insulin Glargine in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Diabetes Mellitus, Type 2","enrollment":387},{"nctId":"NCT00941148","phase":"PHASE4","title":"Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin","status":"COMPLETED","sponsor":"ikfe-CRO GmbH","startDate":"2008-04","conditions":"Type 2 Diabetic Patients, Insufficient Metabolic Control, OAD Treatment","enrollment":30},{"nctId":"NCT00653302","phase":"PHASE4","title":"Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-04","conditions":"Type 2 Diabetes","enrollment":280},{"nctId":"NCT00641407","phase":"PHASE4","title":"Bedtime Insulins and Oral Antihyperglycemic Drugs in Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2007-01","conditions":"Type 2 Diabetes Mellitus, Hypoglycemia","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lantus®, Sanofi"],"phase":"marketed","status":"active","brandName":"Insulin glargine combined with metformin","genericName":"Insulin glargine combined with metformin","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses insulin glargine to provide basal insulin replacement while metformin reduces hepatic glucose production and improves insulin sensitivity. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}